Recombinant human hepatocyte growth factor for liver failure

Contemporary Clinical Trials

Volumn 29, Issue 5, 2008, Pages 696-704

  Cui, Yao Li ^a   Meng, Mao Bin ^a   Tang, Hong ^a   Zheng, Ming Hua ^b   Wang, Yue Bin ^a   Han, Hong Xia ^a   Lei, Xue Zhong ^a  

^a SICHUAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Comprehensive therapy; Hepatocyte growth factor; LF; Meta analysis; Quality assessment

Indexed keywords

RECOMBINANT SCATTER FACTOR;

ARTICLE; CHI SQUARE TEST; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; EMBASE; FEVER; HEADACHE; HUMAN; LIVER FAILURE; MEDLINE; META ANALYSIS; MORTALITY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

CONFIDENCE INTERVALS; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER FAILURE; QUALITY ASSURANCE, HEALTH CARE; RECOMBINANT PROTEINS; RISK;

EID: 49749086116     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2008.04.006     Document Type: Article

References (53)

1. Rahman T.M., and Hodgson H.J. Review article: liver support systems in acute hepatic failure. Aliment Pharmacol Ther 13 10 (1999) 1255-1272
2. Polson J., and Lee W.M. AASLD position paper: the management of acute LF. Hepatology 41 (2005) 1179-1197
3. Wang Y.M. Understanding guidelines of the diagnosis and treatment in LF. Zhonghua Gan Zang Bing Za Zhi 15 8 (2007) 633-636
4. Riordan S.M., and Williams R. Extracorporeal support and hepatocyte transplantation in acute LF and cirrhosis. J Gastroenterol Hepatol 14 8 (1999) 757-770
5. O Grady J.G., Schalm S.W., and Williams R. Acute LF: redefining the syndrome. Lancet 342 (1993) 273-275
6. Wang Y.M., Chen Y.K., Gu C.H., Jiang L., and Xiang D.D. Reevaluation of the nomenclature and diagnostic criteria in 477 patients with severe hepatitis. Zhonghua Gan Zang Bing Za Zhi 8 (2000) 261-263
7. Infectious disease subassociation of LF and artificial liver learning group of Chinese Medicine Association, liver disease subassociation of severe liver disease and artificial liver learning group of Chinese Medicine Association. A guideline: diagnostic and therapeutic of LF. Zhonghua Chuan Ran Bing Za Zhi 24 6 (2007) 422-425
8. Ostapowicz G.A., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute LF at 17 tertiary care centers in the United States. Ann Intern Med 137 (2002) 947-954
9. Acharya S.K., Panda S.K., Saxena A., and Gupta S.D. Acute hepatic failure in India: a perspective from the East. J Gastroenterol Hepatol 15 (2000) 473-479
10. Mizuno S., and Nakamura T. Hepatocyte growth factor: a regenerative drug for acute hepatitis and liver cirrhosis. Regen Med 2 2 (2007) 161-170
11. Uemoto S., Inomata Y., Sakurai T., et al. Living donor liver transplantation for fulminant hepatic failure. Transplantation 70 (2000) 152-157
12. Abe T., Kobata H., Hanba Y., et al. Study of plasma exchange for LF: beneficial and harmful effects. Ther Apher Dial 8 (2004) 180-184
13. Lidofsky S.D. Liver transplantation for fulminant hepatic failure. Gastroenterol Clin North Am 22 (1993) 257-269
14. Ichihara A. BCA, HGF, and proteasomes. Biochem Biophys Res Commun 266 (1999) 647-651
15. Michalopoulos G.K., and DeFrances M.C. Liver regeneration. Science 276 (1997) 60-66
16. Tsubouchi H. Hepatocyte growth factor for liver disease. Hepatology 30 (1999) 333-334
17. Fausto N. Liver regeneration. J Hepatol 32 (2000) S19-31
18. Funakoshi H., and Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin Chim Acta 327 (2003) 1-23
19. Ware L.B., and Matthay M.A. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol 282 (2002) L924-940
20. Xu J.H., Yu Y.Y., Si C.W., et al. Promoting hepatic growth factor in the treatment of heavy type hepatitis and severe chronic hepatitis: a multicenter clinical study. Hepatobiliary Pancreat Dis Int 3 3 (2004) 381-385
21. Kosai K., Matsumoto K., Nagata S., Tsujimoto Y., and Nakamura T. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 244 (1998) 683-690
22. Kosai K., Matsumoto K., Funakoshi H., and Nakamura T. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology 30 (1999) 151-159
23. Wang X., DeFrances M.C., Dai Y., et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 9 (2002) 411-421
24. Nomi T., Shiota G., Isono M., Sato K., and Kawasaki H. Adenovirus-mediated hepatocyte growth factor gene transfer prevents lethal LF in rats. Biochem Biophys Res Commun 278 (2000) 338-343
25. In: Clarke M., and Oxman A.D. (Eds). Cochrane reviewer's handbook 4.2 in review manager (2004), The Cochrane Collaboration, Oxford, UK
26. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 4 (1994) 1088-1101
27. Xu J.Z., Ju J.L., Qi C.Y., et al. A clinical observation of hepatocyte growth factor in the treatment of severe viral hepatitis. Jiangsu Yi Yao 4 (1991) 187-189
28. Hepatocyte growth factor clinical cooperation group. A effective of hepatocyte growth factor in the treatment of 105 cases of severe hepatitis. Guangdong Yi Xue 12 2 (1991) 7-11
29. The special academic exchange convention summary of the hepatocyte growth factor in China (1991). Zhonghua Chuan Ran Bing Za Zhi 10 2 (1992) 124
30. Severe hepatitis therapeutic research cooperation group. A study of severe viral hepatitis (attach to 453 cases effective analysis). Zhongguo Chuan Ran Za Zhi 11 4 (1993) 235-236
31. Zhou D.Y., Mei X.L., Chen A.Z., and Xie H.J. A effect of promoting hepatocyte growth factor in the treatment of severe hepatitis. Hunan Yi Xue 11 4 (1994) 230-231
32. Zhang Y.J., Kong X.P., Zheng G.C., Chen G.M., and Yang F.Q. Evaluation of hepatocyte growth-promoting factors in treating 1687 cases of fulminant hepatitis. Chin Med 108 12 (1995) 928-929
33. Chen C.D. A clinical observation of hepatocyte growth factor in the treatment of severe hepatitis (attach to 30 cases reported). Guangdong Yi Xue 16 2 (1995) 110
34. Xu J.Z., Ju J.L., Wu X.H., et al. A double-blind study of hepatic regenerative stimulus (HRS) on advanced viral hepatitis: analysis of 318 cases. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 9 1 (1995) 42-44
35. Guo X.J., Zhang J.S., Shi Q., and Xiao S.L. Therapeutic efficiency of hepatocyte growth factor on 22 cases of severe viral hepatitis. Lin Chuang Nei Ke Za Zhi 12 4 (1995) 47-48
36. Wang B.L., Lu S.H., He S.R., Zhu Y., Zhang S.Y., and Hong Z.X. A clinical observation of hepatocyte growth factor in the treatment of severe hepatitis. Shi Yong Gan Zang Bing Za Zhi 1 1 (1996) 56
37. Huang X.M., Zuo P.O., Huang T.Z., and Fang Y.S. A clinical observation of promoting hepatocyte growth factor in the treatment of 22 cases of severe hepatitis. Zunyi Yi Xue Yuan Xue Bao 20 1 (1997)
38. He J.S., Zhao L.W., Fan J., and Huang Y.Z. Therapeutic evaluation of the treatment of severe viral hepatitis with promote hepatocyte growth factor. Jiangxi Yi Xue Yuan Xue Bao 37 4 (1997) 75-77
39. Hou W.S. Promoting hepatocyte growth factor in the treatment of 40 cases of severe hepatitis. Wannan Yi Xue Yuan Xue Bao 17 2 (1998) 157-158
40. Liu Z.H., Cai C.W., Xing L.H., Zhang X.T., and Zhang X.S. A clinical effect analysis of hepatocyte growth factor in the treatment of severe hepatitis. Shi Yong Gan Zang Bing Za Zhi 3 2 (1998) 87
41. Zhou X.Q., Si C.W., Wang Z.Q., et al. A multicenter drug therapeutic efficiency of severe hepatitis (attach to 166 cases clinical analyses). Zhonghua Chuan Ran Bing Za Zhi 16 1 (1998) 45-46
42. She H.Y., Zhang H.G., Liu X.Y., and Zhang F. A clinical observation of large doses of promoting hepatocyte growth factor in the treatment of 56 cases of severe hepatitis. Hebei Yi Yao 21 4 (1999) 241-242
43. Huang X.M. A clinical observation of promoting hepatocyte growth factor in the treatment of 34 cases of severe viral hepatitis. Hua Xia Yi Xue 12 6 (1999) 694-695
44. Lai Z.W., Wang Q.Z., and Wen B.X. Research in curative effects on 40 cases with viral hepatitis B by hepatic growth factor. Guangdong Wei Liang Yuan Su Ke Xue 5 (2000) 45-48
45. Zhao G.Q. A clinical observation of the treatment of 80 cases of severe hepatitis with promoting hepatocyte growth factor. Baotou Yi Xue Yuan Xue Bao 17 (2001) 276-277
46. Gao Z.H., and Xuan S.P. A clinical observation of promoting hepatocyte growth factor in the treatment of 30 cases of chronic hepatitis with acute aggravation. Xian Dai Yi Yao Wei Sheng 20 2 (2004) 96-97
47. Sun G., Zhang Y., and Li X.C. A clinical observation of Wei Jia in the treatment of 46 cases of severe hepatitis. Yao Wu Yu Lin Chuang 4 15 (2007) 66
48. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134 (2001) 657-662
49. Lee W.M. Acute LF. N Engl J Med 329 25 (1993) 1862-1872
50. Lwai H., Nagaki M., Naito T., et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med 26 (1998) 873-876
51. Allen J.W., Hassanein T., and Bhatia S.N. Advances in bioartificial liver devices. Hepatology 34 3 (2001) 447-455
52. Sorkine P., Ben Abraham R., Szold O., et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic LF. Crit Care Med 29 7 (2001) 1332-1336
53. Hewitt C., Hahn S., Torgerson D.J., Watson J., and Bland J.M. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ 330 (2005) 1057-1058